Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Opus Genetics, Inc. (IRD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: IRD (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.8
1 Year Target Price $7.8
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -15.75% | Avg. Invested days 31 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 137.93M USD | Price to earnings Ratio - | 1Y Target Price 7.8 |
Price to earnings Ratio - | 1Y Target Price 7.8 | ||
Volume (30-day avg) 3 | Beta 0.41 | 52 Weeks Range 0.65 - 2.59 | Updated Date 01/9/2026 |
52 Weeks Range 0.65 - 2.59 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.86 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -269.93% |
Management Effectiveness
Return on Assets (TTM) -60.74% | Return on Equity (TTM) -338.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 108181416 | Price to Sales(TTM) 9.43 |
Enterprise Value 108181416 | Price to Sales(TTM) 9.43 | ||
Enterprise Value to Revenue 7.39 | Enterprise Value to EBITDA -2.55 | Shares Outstanding 68964208 | Shares Floating 37377911 |
Shares Outstanding 68964208 | Shares Floating 37377911 | ||
Percent Insiders 14.23 | Percent Institutions 27.6 |
Upturn AI SWOT
Opus Genetics, Inc.
Company Overview
History and Background
Opus Genetics, Inc. is a biotechnology company focused on developing gene therapies for inherited retinal diseases (IRDs). Founded in 2019 by researchers at the University of Florida, the company's genesis stems from the discovery of a novel gene therapy approach for X-linked retinitis pigmentosa (XLRP). Opus Genetics has since advanced its lead program into clinical trials and established a pipeline of other potential treatments for rare genetic eye conditions.
Core Business Areas
- Gene Therapy Development for IRDs: Opus Genetics is dedicated to developing and commercializing AAV-based gene therapies for inherited retinal diseases. This includes research, preclinical development, clinical trial execution, and ultimately, regulatory approval and market launch of these novel therapies.
Leadership and Structure
Opus Genetics is led by a management team with expertise in ophthalmology, gene therapy, and drug development. The specific individuals and their roles can be found on the company's official website and in investor relations materials. The organizational structure is typical for a clinical-stage biotechnology company, with departments focused on research and development, clinical operations, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- OPUS-001 (AAV-RS1 for XLRP): A lead gene therapy candidate utilizing an adeno-associated virus (AAV) vector to deliver a functional copy of the RPGR gene, which is deficient in patients with X-linked retinitis pigmentosa. This is Opus Genetics' most advanced program, currently in clinical trials. Competitors in the broader IRD gene therapy space include companies like Applied Genetic Technologies Corporation (AGTC), Biogen (via its acquisition of Nightstar Therapeutics), and Novartis (with Luxturna). Specific market share data for OPUS-001 is not yet available as it is in clinical development.
Market Dynamics
Industry Overview
The gene therapy market, particularly for rare diseases like IRDs, is a rapidly growing and dynamic sector. It is characterized by significant scientific innovation, high development costs, and the potential for transformative patient outcomes. Regulatory pathways for gene therapies are evolving, and there is increasing investment in the field.
Positioning
Opus Genetics is positioned as a specialized gene therapy company focused on addressing unmet needs in inherited retinal diseases. Its competitive advantage lies in its potentially novel gene delivery technology and its focused pipeline targeting specific genetic causes of blindness. The company aims to become a leader in treating rare genetic eye disorders.
Total Addressable Market (TAM)
The TAM for inherited retinal diseases is substantial, with millions of individuals worldwide affected by various forms of genetic blindness. While specific figures for Opus Genetics' targeted indications are still being refined, the combined market for rare IRDs represents a significant opportunity. Opus Genetics is positioned to capture a share of this market by developing effective and approved therapies for these conditions.
Upturn SWOT Analysis
Strengths
- Specialized focus on inherited retinal diseases with significant unmet needs.
- Proprietary gene therapy technology and delivery platform.
- Experienced leadership team with expertise in gene therapy and ophthalmology.
- Lead candidate (OPUS-001) advancing into clinical trials.
Weaknesses
- Clinical-stage company with no approved products, thus no revenue.
- High R&D costs associated with gene therapy development.
- Dependence on successful clinical trial outcomes and regulatory approvals.
- Limited historical financial data as a relatively young company.
Opportunities
- Expanding pipeline to other IRDs beyond XLRP.
- Partnerships and collaborations with larger pharmaceutical companies.
- Advancements in gene editing and other therapeutic modalities.
- Growing investor interest in the gene therapy sector.
Threats
- Clinical trial failures or delays.
- Regulatory hurdles and challenges.
- Competition from other gene therapy developers.
- Reimbursement challenges for novel, high-cost therapies.
- Intellectual property challenges.
Competitors and Market Share
Key Competitors
- Applied Genetic Technologies Corporation (AGTC)
- Biogen Inc. (BIIB)
- Novartis AG (NVS)
Competitive Landscape
Opus Genetics faces competition from established biopharmaceutical companies and other specialized gene therapy developers. Its advantages include its focused approach to specific IRDs and potentially differentiated technology. Disadvantages include its smaller size, limited resources compared to larger players, and the inherent risks associated with early-stage drug development.
Growth Trajectory and Initiatives
Historical Growth: Opus Genetics' historical growth has been driven by scientific discovery, securing initial funding, and advancing its lead gene therapy candidate into clinical trials. The company has expanded its team and scientific capabilities during this period.
Future Projections: Future growth projections for Opus Genetics are heavily dependent on the success of its clinical trials, regulatory approvals, and successful commercialization of its gene therapies. Analyst estimates, when available, will focus on potential peak sales for its pipeline candidates and the expansion of its therapeutic portfolio.
Recent Initiatives: Recent initiatives likely include the initiation and progression of clinical trials for OPUS-001, potential expansion of its research into other IRDs, and efforts to secure further funding through equity offerings or strategic partnerships.
Summary
Opus Genetics is a promising clinical-stage biotechnology company focused on rare inherited retinal diseases. Its strengths lie in its specialized gene therapy approach and experienced team, with a lead candidate showing progress. However, the company faces significant risks inherent in drug development, including clinical trial failures and regulatory hurdles. Strong execution, continued innovation, and successful fundraising will be crucial for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company publicly available filings (e.g., SEC filings, press releases)
- Industry reports and market analysis
- Financial data aggregators
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. Data is based on publicly available information and may not be exhaustive or up-to-date. Investment decisions should be made in consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Opus Genetics, Inc.
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2005-05-23 | CEO & Director Mr. George Magrath M.B.A., M.D., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 18 | Website https://opusgtx.com |
Full time employees 18 | Website https://opusgtx.com | ||
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances; and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.